Clinical Trial: A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07185776) titled 'A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events' on Sept. 15.

Brief Summary: The main purpose of this study is to evaluate the efficacy and safety of HRS-5632 in adult participants with elevated Lipoprotein(a) (Lp(a)) at high risk for cardiovascular events.

Study Start Date: Oct., 2025

Study Type: INTERVENTIONAL

Condition: Lipoprotein Disorder

Intervention: DRUG: HRS-5632 Injection

HRS-5632 injection.

DRUG: HRS-5632 Injection Placebo

HRS-5632 injection placebo.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.

Published b...